Avalon GloboCare(ALBT)

Focus: Avalon GloboCare is a publicly traded biotechnology company focused on cell therapeutics and technology, specifically developing CAR-T immunotherapies for hematologic malignancies. The company is early-stage with minimal revenue generation and a single clinical program in Phase 1.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Avalon GloboCare

AI assessmentNot Hiring

No open roles listed right now. Follow Avalon GloboCare to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

1 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Revenue

$0K

FY2025

Pipeline & Clinical Trials

CD19-CAR-T

B-cell Malignancy

Phase 1

Clinical Trials (1)

NCT03952923CD19-CAR-T in B-cell Malignancies Patients

Phase 1

Help build intelligence for Avalon GloboCare

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to cutting-edge CAR-T cell therapy technology in a focused, early-stage environment where individual contributions drive pipeline advancement
Public company status provides equity liquidity and institutional credibility absent in private pre-revenue biotech
Opportunity to shape a nascent organization's culture and scientific direction from the ground up

Watch Out For

Severe cash constraints ($3M in FY2025, down from $285K in FY2024) create immediate runway concerns and potential dilution risk for employees
Single Phase 1 program with no marketed products, published research, or clinical validation represents extraordinarily high execution risk
Net losses exceeding $7.9M annually with minimal R&D spend ($35K in FY2024) suggest potential underfunding or resource misallocation

Generated by Claude from Avalon GloboCare's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2016

Portfolio: 1 clinical trial

SEC Filings: 2 available

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Financials (FY2025)

Revenue

$0100%

Net Income

-$8M

Cash

$3M

Source: SEC 10-K Filing